Brought to you by 
Ziarco gets four therapeutic programs from Pfizer
03 Dec 2012
Executive Summary
Concurrent with its $27mm Series A financing in which Pfizer Venture Investments participated, newly created Ziarco Pharma Ltd. received exclusive worldwide rights to develop and commercialize four Pfizer programs in the areas of inflammatory and allergic diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ziarco gets four therapeutic programs from Pfizer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice